Pfizer announced a $4.9 billion deal to acquire Metsera, regaining a foothold in the obesity treatment space. Metsera’s pipeline includes oral and injectable incretin-based therapies aimed to improve dosing convenience and tolerability. The acquisition complements Pfizer's existing metabolic disorder portfolio and aims to capture growing demand in obesity therapeutics. Key Phase 2 trial readouts for Metsera’s lead GLP-1 candidate are expected in 2026. The move positions Pfizer as a competitive player in a rapidly expanding market sector.